Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to macroalbuminuria Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to macroalbuminuria · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
UACR (% change) ( · preventing the progression of CKD
1 finding from 1 review
Health‐related quality of life Mean AcroQoL score (0‐100) · adults with growth‐hormone secreting pituitary adenomas
Surgery alone showed no clear difference in health‐related quality of life Mean AcroQoL score (0‐100) compared with pharmacological therapy alone (low certainty).
1 finding from 1 review
QoL · adults and children with cystic fibrosis
1 finding from 1 review
Intracranial haemorrhage · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation
Summary of findings table ‐ Starting long‐term therapeutic dose oral… showed no clear difference in intracranial haemorrhage compared with avoiding anticoagulation (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review
Intracranial hemorrhage on imaging at 24 hours · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in intracranial hemorrhage on imaging at 24 hours compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage at · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in symptomatic intracranial hemorrhage at 24 hours compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Pain intensity (mean across treatment or at end of treatment; length of treatment varied across trials; various pain intensity scales; SMD) · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes pain intensity (mean across treatment or at end of treatment; length… compared with IR oxycodone (very low certainty).
1 finding from 1 review
Constipation · adults with cancer‐related pain
It is very uncertain whether CR oxycodone changes constipation ‐ only English language studies (Event rate during… compared with CR morphine (very low certainty).
2 findings from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · adults with cancer‐related pain
CR oxycodone showed no clear difference in drowsiness/somnolence (Event rate during treatment, length of… compared with CR morphine (low certainty).
1 finding from 1 review
Nausea · adults with cancer‐related pain
CR oxycodone showed no clear difference in nausea (Event rate during treatment, length of treatment varied… compared with CR morphine (low certainty).
1 finding from 1 review